Pharmaco-miR:linking microRNAs and drug effects by Rukov, Jakob Lewin et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Pharmaco-miR
Rukov, Jakob Lewin; Wilentzik, Roni; Jaffe, Ishai; Vinther, Jeppe; Shomron, Noam
Published in:
Briefings in Bioinformatics
DOI:
10.1093/bib/bbs082
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Rukov, J. L., Wilentzik, R., Jaffe, I., Vinther, J., & Shomron, N. (2014). Pharmaco-miR: linking microRNAs and
drug effects. Briefings in Bioinformatics, 15(4), 648-659. https://doi.org/10.1093/bib/bbs082
Download date: 02. Feb. 2020
Pharmaco-miR: linking microRNAs
and drug effects
Jakob Lewin Rukov*, Roni Wilentzik*, Ishai Jaffe, Jeppe Vinther and Noam Shomron
Submitted: 11th July 2012; Received (in revised form): 19th November 2012
Abstract
MicroRNAs (miRNAs) are short regulatory RNAs that down-regulate gene expression. They are essential for cell
homeostasis and active in many disease states. A major discovery is the ability of miRNAs to determine the efficacy
of drugs, which has given rise to the field of ‘miRNA pharmacogenomics’ through ‘Pharmaco-miRs’. miRNAs play a
significant role in pharmacogenomics by down-regulating genes that are important for drug function. These inter-
actions can be described as triplet sets consisting of a miRNA, a target gene and a drug associated with the gene.
We have developed a web server which links miRNA expression and drug function by combining data on miRNA
targeting and protein^ drug interactions. miRNA targeting information derive from both experimental data and
computational predictions, and protein^ drug interactions are annotated by the Pharmacogenomics Knowledge
base (PharmGKB). Pharmaco-miR’s input consists of miRNAs, genes and/or drug names and the output consists of
miRNA pharmacogenomic sets or a list of unique associated miRNAs, genes and drugs.We have furthermore built
a database, named Pharmaco-miR Verified Sets (VerSe), which contains miRNA pharmacogenomic data manually
curated from the literature, can be searched and downloaded via Pharmaco-miR and informs on trends and general-
ities published in the field. Overall, we present examples of how Pharmaco-miR provides possible explanations for
previously published observations, including how the cisplatin and 5-fluorouracil resistance induced by miR-148a
may be caused by miR-148a targeting of the gene KIT. The information is available at www.Pharmaco-miR.org.
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INTRODUCTION
MicroRNAs (miRNAs) are short (22 nucleotides)
regulatory RNAs that down-regulate gene expres-
sion at the posttranscriptional level by inhibiting
translation or initiating mRNA degradation [1, 2].
The mature miRNA functions in the RNA-induced
silencing complex (RISC) [3] and recognizes its
mRNA targets by a system of partial complementar-
ity between the miRNA and the 30UTR of
the target gene [1, 2, 4]. In the ‘miRbase’ database
of miRNAs [5], 2042 human mature miRNAs are
registered, although the role of many of these is still
unclear. miRNA target genes are available from
a variety of sources, including computational predic-
tions [6–8], single gene studies [9, 10] and, most
recently, large-scale experimental studies that com-
bine cross-linking of loaded RISC complexes
to target UTRs, immunoprecipitation and next-
generation sequencing to identify miRNA targets
[11–13].
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More than half of human genes are likely targets of
evolutionarily conserved miRNA regulation [14].
miRNAs are therefore important regulators of gene
expression, andmany cellular processes, including dif-
ferentiation, apoptosis and stress responses, are con-
trolled by miRNAs [15]. miRNAs are essential for
cell homeostasis and tissue identity, regulate many
disease provoking genes and are as such implicated
in many diseases, including diabetes [16], neurological
diseases [17] and cardiovascular diseases [18]. They are
significantly deregulated in cancer [19] and individual
types of cancer can in fact be defined and identified by
their miRNA profile [19–21]. miRNAs are therefore
broadly recognized to have great potential, both
within diagnostics and therapeutics.
A recent major observation involving a new role
for miRNAs is their ability to determine the efficacy
of drugs. These findings gave rise to the field of
miRNA pharmacogenomics [22]. Traditionally,
pharmacogenomics deals with how genomic vari-
ations, for instance sequence variation within specific
genes, determine drug function. One ultimate aim of
pharmacogenomics is to predict which drugs will be
the most effective and safe for a patient based on
individual genomic and transcriptomic features,
thereby allowing personalized treatment strategies.
Pharmacogenomics therefore has great clinical po-
tential. The majority of pharmacogenomic research
to date has focused on the role of single-nucleotide
polymorphisms (SNPs), variations in unique DNA
nucleotides in the genome and studying copy
number variations (duplications or deletions of
genes or larger genomic segments). Alternative
mRNA splice patterns and differences in gene ex-
pression levels constitute other research strategies
within pharmacogenomics.
AROLE FORmiRNAs IN
PHARMACOGENOMICS
Many drugs require the expression of specific genes
to function, and drug function can be affected by
changes in the expression level of these pharmaco-
genomic genes. miRNAs are essential for tissue iden-
tity and hardwired into cell-specific regulation. As
such miRNAs regulate many genes involved in
pharmacogenomics. Furthermore, the transition
from healthy to disease tissue is accompanied by ex-
tensive changes in miRNA profiles. These changes
may either be a direct cause of the disease or a sec-
ondary effect of other regulatory changes in the cell
[20]. The change may in both cases be important for
the expression of pharmacogenomic genes. Finally,
tissues deriving from the same disease, for instance
tumors of the same type, can vary in their miRNA
profile between patients [19]. miRNA profiling is
therefore used to sub-categorize cancers and other
diseases [19–21]. These differences in miRNA pro-
files may be fundamental in miRNA pharmacogen-
omics, since different profiles will affect
pharmacogenomics related genes differently, with
extensive downstream consequences for drug effect.
In support of this, there is evidence that variations in
miRNA patterns in similar diseases do in fact lead to
differences in gene expression [23, 24]. If genes af-
fected by such differences are involved in drug func-
tion, the efficacy of the drug may also be affected.
It is therefore not surprising that a series of recent
miRNA pharmacogenomic studies document how
miRNAs are important for the ability of drugs to
induce their effect (reviewed in [25]). In general,
these studies identify miRNA targets in genes that
are also known to bind or transport chemotherapeu-
tic drugs. They then show that affecting gene expres-
sion with varying levels of miRNAs also affects the
efficacy of the drugs known to depend on the gene
for its function. One example of this is the import-
ance of miR-125b for calcitriol (active vitamin D)
efficacy in breast cancer MCF-7 cells. Calcitriol binds
to the vitamin D receptor (VDR) and thereby in-
duces the formation of an active transcription factor
complex. Mohri et al. [26] have shown that VDR
protein levels are lowered by miR-125b. When
this occurs, the efficacy of calcitriol is similarly
decreased, resulting in higher cancer cell proliferation
(Figure 1A).
miRNA PHARMACOGENOMIC
SETS:THE LINEARRELATIONSHIP
BETWEENmiRNAs, GENESAND
DRUGS
As exemplified above, the principle of miRNA
pharmacogenomics entails that increased miRNA
expression down-regulates genes encoding proteins
that promote drug efficacy. Conversely, lowered
miRNA levels may result in up-regulated genes
with products that inhibit drug function. Both
these processes may affect drug function and there-
fore make miRNAs indirect, potentially potent
regulators of drug efficacy. Thus, the role of
miRNAs in pharmacogenomics can conceptually
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be viewed as collections of miRNA pharmacoge-
nomic sets consisting of miRNA, gene and drug
(Figure 1B). According to this model, a miRNA af-
fects drug function via the regulation of a gene
whose protein product interacts with that drug. For
example, since 125b targets VDR and thereby affects
calcitriol function, miR-125b–VDR–calcitriol con-
stitutes a miRNA pharmacogenomic set (Figure 1A).
Pharmaco-miRVerSe: A DATABASE
OF miRNA PHARMACOGENOMIC
SETS
Here, we present a database of experimentally
verified miRNA pharmacogenomic sets consisting
of a miRNA, a target gene and a drug depending
on the gene for its function. The database is named
Pharmaco-miR Verified Sets (VerSe). It has been
built as part of the Pharmaco-miR web server and
is available for download on the server at Pharmaco-
miR.org. While the Pharmaco-miR web server
includes the VerSe database, it also offers parsing
and data filtering, as will be described below. The
miRNA pharmacogenomic sets in Pharmaco-miR
VerSe are curated from published studies. As also
exemplified above, two aspects can be said to char-
acterize miRNA pharmacogenomic sets and have to
be fulfilled for inclusion in Pharmaco-miR VerSe:
(1) the miRNA must be shown to target the gene
directly in the specified context (typically shown by
luciferase experiments) and (2) the subsequent inhib-
ition of gene expression must affect drug efficacy in
the same context. Based on these criteria, we have
collected miRNA pharmacogenomic sets described
in the literature. The database consists of 269 phar-
macogenomic sets annotated from 149 original art-
icles. The sets encompass 105 miRNAs, 119 genes
and 72 drugs (Table 1).
AGROWING FIELD
Looking at the articles in VerSe reveals a steady in-
crease in the number of publications in miRNA
pharmacogenomics. The first article to present a
miRNA pharmacogenomic set (and therefore the
earliest set in Pharmaco-miR VerSe) was published
in 2007 by Mishra et al. [27]. This first example of
miRNA pharmacogenomics is slightly atypical, since
A B C D
Figure 1: (A) An example of an experimentally verified miRNA pharmacogenomic set. miR-125b inhibits vitamin
D receptor (VDR) expression.VDR is a co-factor for calcitriol, and lower protein levels decrease calcitriol efficacy
[26]. (B) The concept of miRNA pharmacogenomics.While increased levels of miRNA always inhibits gene expres-
sion, protein levels can either increase or decrease drug response, depending on protein function. Together, a
miRNA, a target gene and a drug that interacts with the target gene’s product forms a miRNA pharmacogenomic
set. (C) Sources integrated in Pharmaco-miR. miRNA targets are fetched fromVerSe, miRecords [10], miRTarBase
[9], TargetScan [14], miRanda [7] and PITA [8], and gene^ drug interactions are from VerSe or annotated by the
Pharmacogenomics Knowledge Base [37]. (D) The conceptual difference between searching for ‘all associations’
and ‘overlapping associations’. When searching for all associations, the output consists of all miRNA pharmacoge-
nomic sets which contain at least one of the input parameters, while when searching for overlapping associations
the output consist of miRNA pharmacogenomic sets that contain objects which are shared by all the search terms
entered. In this example, by entering three genes as the search entries and choosing ‘all associations’, both miR-A
and miR-C are included with one set each (miR-A^Gene 1^Drug 1 and miR-C^Gene 3^Drug 3, respectively),
while miR-B occurs in three sets (miR-B^Gene 1^Drug 1, miR-B^Gene 2^Drug 2 and miR-B^Gene 3^Drug 3).
However, when choosing ‘overlapping associations’, at least one component in every output set must be associated
with all the search entries. In this example, only miR-B connects all three genes entered. Thus, only sets with
miR-B occur in the output, while sets with miR-A and miR-C are not included. Notice that in this case, it is not ne-
cessary for any of the drugs to be associated with all three genes; it is sufficient that they occur in sets where
miR-B is also present.
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obstructed miRNA function occurs due to a SNP in
a miR-24 target site in the gene dihydrofolate re-
ductase, affecting methotrexate efficacy. Since then,
miRNA pharmacogenomic papers have steadily
increased in frequency, with 46 papers in 2011 and
57 expected for 2012 (Figure 2).
THE CENTRALROLEOF miR-21
One trend apparent in Pharmaco-miR VerSe is that
many published miRNA pharmacogenomic sets con-
tain miR-21. In fact, 24 of 269 unique sets in
Pharmaco-miR VerSe include miR-21. It has, for
instance, been shown to affect 5-flouruoracil (5-FU)
action alone through targets in SPRY2 [28], PDCD2
[29], PTEN [29] and MSH2 [30]. While some of the
many examples of miR-21 effect on drug function
may partly be due to the large focus on miR-21 in the
RNA community, it also fits well with the important
role of miR-21 as an ‘onco-miR’, targeting many
tumor suppressor genes, among them PTEN
[29, 31, 32] and PDCD4 [32, 33].
Due to the important role for these genes in cancer,
they are also central in chemotherapy. For example,
miR-21 regulates drug efficacy and also has a part
regulating tumorigenesis [30]. MSH2, for instance,
encodes a DNA tumor suppressor protein involved
in DNA repair, and its disruption leads to an increased
mutational rate in cancer cells. The 5-FU, on the
other hand, has an anti-cancer effect, since 5-FU me-
tabolites are incorporated into and disrupt the DNA
of proliferating cells. MSH2 and 5-FU therefore both
have related to DNA replication and repair. Although
MSH2 is a tumor suppressor, its gene product in-
creases the efficacy of 5-FU, since it promotes incorp-
oration of 5-FU metabolites into DNA. Therefore,
during 5-FU treatment, decreased MSH2 levels, for
instance after miR-21 targeting, attenuates the effect
of 5-FU, and increased miR-21 levels leads to 5-FU
resistance [30]. Thus, the same factors that make
miR-21 central in cancer also provide miR-21 with
the ability to strongly regulate drug efficacy, testifying
to the link between cancer miRNAs and
Pharmaco-miRs.
LIMITATIONSTOTHEmiRNA
PHARMACOGENOMIC
EXPERIMENTALMODEL
The focus on cancer miRNAs and chemotherapeu-
tics hints at a common structure of many miRNA
pharmacogenomic studies. Drug-resistant cancer cell
Table 1: Databases included in Pharmaco-miR
Conserved
miRNAsa
Nonconserved
miRNAs
miRNA^gene
links
Genes Gene^drug
links
Drugs
miRTarBase 227 998 466
miRecords 132 375 215
Targetscan
Conserved targets 247 402 28 436 1615
Non-conserved targets 249 428 191834 2300
Total 249 428 211795 2280
miRanda
High mirSVR 249 851 365910 2307
Low miRSVR 249 851 674 011 2312
Total 249 851 884911 2316
PITA
Top predictions 673 30752 1365
All predictions 677 526 624 2198
VerSe 105 190 119 210 72
PharmGKB 2397 11300 921
Total 1154 1026 667 2463 11482 951
aIncludes broadly conserved TargetScanmiRNAs.
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Figure 2: The increasing number of yearly papers
included in Pharmaco-miRVerSe.
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lines are developed (often accompanied by miRNA
deregulation as the cells become resistant), changes in
miRNA and mRNA expression are monitored, a
candidate miRNA (and consequently also its target
gene) is perturbed and this interaction is shown to
reinstate drug sensitivity. This last point is deter-
mined by two phenotypes that are typical for
cancer: apoptosis and cell invasiveness after addition
of the drug. While this model is both elegant
and experimentally straightforward, it is by nature
limited to chemoresistance studies. Testing non-
chemotherapeutic drugs is more experimentally
challenging, since they in most cases require other
proxies for drug efficacy.
Similarly, toxicity studies are remarkably absent
from miRNA pharmacogenomic literature, most
likely due to the lack of an experimental model that
can be broadly applied. As the field of miRNA
pharmacogenomics develops, one challenge will be
studying links between miRNAs and drug toxicity.
Another type of studies only rarely performed link
drug metabolism and miRNA activity. One explan-
ation for this may be that many drugs are primarily
metabolized in the liver while they function in other
tissues. In this case, standard stable cell line experi-
ments do therefore not suffice.
Only two studies in the VerSe database (which
describe full miRNA pharmacogenomic sets) include
members of the cytochrome P450 families, the major
group of drug metabolizing enzymes. Komagata et al.
[34] showed that miR-125b affects calcitriol efficacy
by targeting CYP24A1, a calcitriol metabolizer.
However, this case is not typical, since the drug in
this example is metabolized and performs its function
(binding to the vitamin D receptor) in the same
tissue (MCF-7 breast cancer cells). Similarly, Pan
et al. [35] induced CYP3A4 in pancreas cancer cells
which activated cyclophosphamide to produce cyto-
toxic agents. Introducing miR-27a down-regulated
CYP3A4 expression and simultaneously attenuated
the cytotoxic effect of cyclophosphamide. Thus, in
both the above cases, drug metabolism and function
occurred in the same tissue, unlike what is the case in
most in vivo situations.
We have previously shown that miRNA targets are
significantly underrepresented in genes that metabol-
ize drugs when compared with genes in general [36].
However, considering the large number of drugs po-
tentially metabolized by a few enzymes, the pharma-
cokinetic impact of a single miRNA target in one
gene can be quite dramatic. CYP3A4 is thought to
be involved in the metabolism of more than half of all
drugs, and it is associated with 243 drugs and drug
classes according to PharmGKB, a valuable source of
accumulating knowledge within the pharmacogen-
omics field [37]. One future challenge, to identify
the true scope of miRNA pharmacogenomics, is
therefore to apply new experimental setups, for in-
stance to animal models, so that miRNA targeting
and drug action can be tested in different tissues.
These above examples illustrate how limitations in
methodology and hypothesis building may limit the
scope of the studies performed, and the pervasiveness
of miRNA pharmacogenomics may be broader than
work done to date within the research area indicates.
In general, a major limitation within miRNA
pharmacogenomics today is determining the mech-
anism of action linking miRNAs and drug response.
In hindsight, the mechanism is often obvious as
exemplified by Mohri et al. [26], but the denovo iden-
tification of such triplet sets of interdependent mol-
ecules (miRNAs, genes and drugs) is very
challenging, since a plethora of miRNA targets and
gene drug dependencies exist, creating a virtually
endless number of possible combinations. It is thus
a continuous challenge for miRNA pharmacoge-
nomic studies to determine the exact associations be-
tween miRNAs, genes and drugs and thereby
identify valid miRNA pharmacogenomic sets. For
instance, miRNAs are often found to be perturbed
in drug-resistant cells [26, 38–40]. There is, however,
no necessary causal connection between such
deregulated miRNAs and the drug resistance pheno-
type. On the other hand, identifying potential con-
nections between perturbed miRNAs and the drug
resistance phenotype would contribute important in-
formation about the mechanism of drug resistance
and facilitate the use of miRNA profiling to predict
drug responses. In particular, the challenge is to iden-
tify possible miRNA targets that may at the same
time be effector genes generating drug resistance.
In other cases, specific sets of genes may be deregu-
lated in drug-resistant cells, but the underlying regu-
latory reason (for instance involving miRNA
regulation) will be difficult to predict. In a clinical
context, the challenge will be to predict which drugs
may show unwanted efficacy and toxicity effects
based on miRNA expression profiling alone.
Establishing candidate miRNA pharmacogenomic
interactions as outlined above has demanded exten-
sive searches in miRNA targeting databases (typically
consisting of computational predictions; detailed
652 Rukov et al.
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later in the text), drug databases such as the
PharmGKB [37] as well as biomedical literature to
produce the link between miRNA targeting and
genes relevant for drug efficacy. Many studies there-
fore fall short of identifying the full drug resistance
pathway, and some offer two out of the three com-
ponents, usually drugs and miRNAs [38–40].
To assist in determining such complete miRNA-
pharmacogenomic sets of miRNAs, their target
genes and the associated drugs, we have constructed
a web server named Pharmaco-miR (www.
pharmaco-miR.org). Pharmaco-miR accepts
miRNA, gene and drug names as input and provides
the relevant associated miRNA pharmacogenomic
sets as output. The database combines data from a
variety of sources, including several miRNA target
prediction databases, curated literature of experimen-
tally validated miRNA target genes and published
gene–drug interactions as annotated by PharmGKB
or in the VerSe database that accompanies the web
server. Thus, Pharmaco-miR allows researchers to
quickly and uniquely determine which miRNAs,
genes and drugs may interact in a pharmacogenomic
context.
miRNADATA INTEGRATION
Pharmaco-miR is designed to determine miRNA
pharmacogenomic sets, consisting of a miRNA, a
target gene and a drug described in literature as
being associated with the target gene. To this end, a
variety of databases have been integrated (Figure 1C).
Two databases, miRecords [10] and miRTarBase [9],
collect experimentally verified miRNA targets as
described in the literature. Although the number of
validated targets is growing fast, only a small fraction is
thought to have been identified so far.
Pharmaco-miR therefore also includes several data-
bases of computational miRNA target predictions:
TargetScan [6, 14], miRanda [7, 41] and PITA [8]
(Table 1). The different database methodologies are
described below, and the data files used in
Pharmaco-miR are described in the Supplementary
Materials accompanying this article.
COMPUTATIONALmiRNATARGET
PREDICTIONS
TargetScan was the first miRNA target database
published [6]. It was originally launched as part of
the first major target search, revealing the importance
of the ‘seed’ region [6], but has been regularly
updated and improved [14]. The database includes
all potential target sites with minimum a 6mer seed
match but does not allow for mismatches in the seed
sequence. It permits stringent filtering based both on
target conservation and conservation of the miRNA
family. Target sites can furthermore be evaluated
based on seed type and context contribution as
well as depth of evolutionary conservation [6, 14].
The version of TargetScan included in Pharmaco-
miR is 5.2.
The miRanda algorithm [7] uses less stringent
criteria than TargetScan for prediction of target
sites. miRNA are aligned to mRNAs to identify
complementarity, but while seed match is weighed
more strongly, G:U wobble base pairing and mis-
matches in the seed do not lead to exclusion from
the set of predictions [7]. Similarly, the algorithm
considers conservation throughout the potential
miRNA matching region rather than only seed con-
servation. Targets are scored based on the free energy
of the mRNA:miRNA heteroduplex. miRanda
therefore includes de facto targets that may be
missed by more stringent algorithms; however, this
increase in sensitivity is likely accompanied by a sig-
nificant loss of specificity. The version of miRanda
used in Pharmaco-miR is the August 2010 release.
PITA [8] differs from the two above algorithms
mainly by considering not only the miRNA:mRNA
match but also structural features surrounding the
putative target site and the energy cost to open and
expose the target site to the miRNA-loaded RISC.
Full seed match is required for 6mer sites, while
7mer and 8mer matches are allowed one wobble
G:U pair. Catalog version 6 of PITA is used in
Pharmaco-miR.
GENE^DRUGASSOCIATIONS
Information on gene–drug associations is based
on literature annotations from two different sources.
The majority of drugs (921) derive from PharmGKB,
which among other things include a list of genes and
drugs which have been linked experimentally ac-
cording to the literature. The PharmGKB drugs are
linked to 2397 genes. Other gene–drug associations
derive from the database VerSe build specifically for
Pharmaco-miR. Both are built from literature anno-
tations. The VerSe database contains 269 sets, linking
119 genes and 73 drugs (Table 1).
Pharmaco-miR 653
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WORKFLOW
Pharmaco-miR searches are performed by entering
the name of a gene, drug and/or miRNA of interest
in the search field. The search page also contains an
option to change query features and the databases
searched. Using the default options, the Pharmaco-
miR output consists of detailed miRNA pharmaco-
genomic sets of miRNAs, genes and drugs. Also, in
the database features, sets and subsets of miRNA
target predictions may be picked. These choices
vary depending on the structure of the different data-
bases. For TargetScan, conserved and non-conserved
miRNA targets may be searched independently, and
miRNAs with varying levels of conservation may
be included in the search. Similarly, conserved and
non-conserved targets may be selected for miRanda
which also allows for searching different miRSVR
scores, an indicator of the efficacy of the target site
[41]. PITA targets are separated into top targets,
which are the most likely to be functional miRNA
binding sites, or can be expanded to include all pre-
dicted miRNA targets.
‘DETAILEDASSOCIATIONSTABLE’
AND ‘REDUCEDASSOCIATIONS
TABLE’ IN QUERY FEATURES
As mentioned above, Pharmaco-miR output consists
of detailed miRNA pharmacogenomic sets of
miRNAs, genes and drugs, available when choosing
the default ‘detailed association table’ option.
A reduced output option (‘reduced associations
table’) may also be chosen in the query features
and results in a list of unique miRNA/gene/drug
names, where each name occurs only once. Thus,
this output option does not inform on the specific
miRNA pharmacogenomic sets but shows the names
of all objects in the sets without duplications. This
feature is useful to get an overview of larger datasets.
RANKINGTHE PREDICTIONS
Setting the search options provides the initial filter-
ing of Pharmaco-miR predictions. However, it will
often be necessary to further sort the sets. Pharmaco-
miR predictions derive from a variety of sources, and
targets are generated and scored on the basis of dif-
ferent algorithms that cannot be easily aligned.
Pharmaco-miR predictions can therefore be scored
on the basis of the original ranking system for the
different target predictors. This statistical information
can be accessed by selecting the ‘Associations
Statistics’ checkbox in the results page. For
TargetScan, Context Scores are given, for miRanda
the mirSVR score and for PITA the total free energy
score. These scores are described in more detail on
the web server. For the remaining databases, which
are all based on literature annotations, the number of
papers describing the associations is given as a proxy
for the support for the association.
‘ALLASSOCIATIONS’AND
‘OVERLAPPINGASSOCIATIONS’
IN QUERY FEATURES
The output miRNA pharmacogenomic sets may be
generated by two different methods: the default ‘all
associations’ output provides all miRNA pharmaco-
genomic sets which contain at least one of the search
input terms. While this gives the largest amount of
information, it may in some cases be preferable to
focus only on sets that share some components. For
instance, if experiments reveal that some miRNAs are
perturbed in drug-resistant cells, it may be interesting
to know whether these miRNAs may have an addi-
tive effect on drug resistance, even though they do
not target the same genes. In this case, ‘overlapping
associations’ should be selected rather than ‘all associ-
ations’. In the ‘overlapping associations’ analysis, all
sets must contain at least one component that
co-occurs with all the entered search terms (Figure
1D). If miRNAs are entered, for instance, all sets in
the output will contain a gene that is targeted by all
entered miRNAs and/or a drug which may be af-
fected by all the miRNAs, possibly through the ac-
tions of different genes. This gene/drug in question
will then be shown with bold letters in the output.
EXPORTANDLINKS
An export option allows the tables in Pharmaco-
miR to be exported (as comma delimited .csv files)
and automatically opened in Microsoft Excel.
Furthermore, a series of links couple the output
with the background databases. Since the informa-
tion in Pharmaco-miR largely consists of data inte-
grated from other sources, it may be important to
refer back to these sources to gain more detailed
knowledge on parts of the Pharmaco-miR output.
Also, since associations are partly based (when using
computational miRNA target predictions) or fully
based (when validated targets are used) on literature
654 Rukov et al.
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annotations, links are also provided to PubMed
entries for relevant papers.
USING Pharmaco-miR
PREDICTIONS
A simple way of using Pharmaco-miR is looking for
miRNA targets in genes relevant for pharmacogen-
omics. A search among such genes reveals that many
genes have experimentally confirmed miRNA tar-
gets, but the target has not been studied in a pharma-
cogenomic context. It can therefore be hypothesized
that the effect of these drugs may be influenced by
perturbations in the predicted miRNAs. For instance,
the anticoagulant warfarin has a narrow therapeutic
window and is the leading cause of adverse drug
event-related hospitalizations in the United States
[42]. Warfarin is metabolized in part by CYP1A1,
and the CYP1A1 gene carries an experimentally con-
firmed miR-125b target. It is therefore plausible that
the optimal dose of warfarin depends on, among
other factors, the level of miR-125b.
The difficulty in identifying full miRNA pharma-
cogenomic sets is exemplified in the many studies
that succeed in determining which miRNAs are
deregulated in drug-resistant cells, but then fail to
determine the relevant target genes and therefore
the mechanism of action that generates drug resist-
ance. For instance, Hummel et al. convincingly show
that miR-148a induces sensitivity to cisplatin and
5-FU in previously resistant esophageal adenocarcin-
oma (EAC) and squamous cell carcinoma (SCC) cell
lines, however, they do not identify relevant target
genes [38]. Using default Pharmaco-miR search set-
tings, five sets containing miR-148a and cisplatin are
identified (as shown in Table 2) and may contain
relevant effector genes for cisplatin resistance.
Among them is the gene KIT which encodes a sig-
naling protein with oncogenic potential.
Interestingly, inhibition of KIT signaling has been
shown to increase responsiveness to cisplatin in ovar-
ian cancer cells [43]. It is therefore possible that a
similar mechanism exists in EAC and SCC cells,
so miR-148a down-regulates KIT and, by inhibiting
its signaling activity, increases cisplatin efficacy.
This is only one example of the usefulness of
Pharmaco-miR in hypothesis building and experi-
mental planning.
That said, it is important to note that both
miRNA targeting of genes and gene–drug inter-
actions vary in a context-dependent manner, and
some of the output of Pharmaco-miR is based on
computational predictions only. The predictions
made by the web server, therefore, do not replace
experimental verification but rather provide a signifi-
cant and useful focus for such experiments. Stronger
predictions can be achieved by using only experi-
mentally verified targets or targets with strong statis-
tical support, and more sets, although less likely to be
functional, can be searched by adding low-value
databases or databases with nonconserved miRNA
targets.
Moreover, Pharmaco-miR can be used to build
hypothesis on which functionally important miRNA
pharmacogenomic sets may not yet been identified.
For instance, six genes very important in pharmaco-
genomics (named VIP genes by PharmGKB) contain
miRNA targets that have previously been validated
experimentally (Table 3). These genes are in turn
associated with the function of dozens of drugs,
some of which are listed in Table 3. Only
very few of these sets (such as miR-125b–VDR–
calcitriol) have been tested in a pharmacogenomic
context (and is therefore included in VerSe).
However, the strict criteria for target selection (ex-
perimental testing) and the well-studied gene–drug
relationships (as VIP genes) increase the likelihood
that these sets are relevant for miRNA pharmaco-
genomics and therefore worth studying
experimentally.
For instance, in the folate cycle, thymidylate
synthetase (TYMS) catalyzes the methylation of
dUMP to dTMP and is essential for the synthesis
of dTTP and hence for de novo DNA synthesis.
Table 2: Examples of papers that identify deregulated
miRNAs in drug resistance, but not the effector genes,
and the genes suggested by Pharmaco-miR
Study Resistance
drug
Deregulated
miRNA
Pharmaco-miR
putative
effector gene
Hummel et al. [38] Cisplatin miR-148a ATP7A
Cisplatin miR-148a KIT
Cisplatin miR-148a ERBB3
Cisplatin miR-148a PTEN
Cisplatin miR-148a LRP2
Dai et al. [40] Docetaxel miR-130a TGFBR2
Docetaxel miR-130a CDKN1A
Docetaxel miR-130a PTEN
Docetaxel miR-181d MAPT
Docetaxel miR-181d BCL2
Bian et al. [39] Cisplatin miR-451 CDKN2D
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TYMS is therefore an important target for anti-
cancer and immunosuppressant drugs such as metho-
trexate [44], and overexpression of TYMS has been
linked to drug resistance [45]. Since TYMS is a
verified target of let-7b, it is possible that let-7b
(and possibly other miRNAs in the let-7 family)
influences the effect of at least some of the many
associated drugs. If this is true, let-7b mimics may
have potential as adjuvant therapeutics to counter
TYMS-related drug resistance. Over-expression of
let-7b in, for instance, solid tumors may also indicate
a high likelihood of treatment success for drugs
targeting the folate cycle, such as methotrexate.
LIMITATIONSTOAONEmiRNA,
ONEGENE, ONEDRUGMODEL
As apparent from above, the concept of one miRNA
regulating one gene affecting response to one drug
may not take the full scope of miRNA regulation
into account. For instance, the same miRNA may
target multiple genes that are relevant for the func-
tion of one particular drug [46, 47] as exemplified by
the several miR-125b target genes in calcitriol resist-
ance affecting both the drug’s metabolism and its
target protein level [26, 34]. In the context of
Pharmaco-miR, the same gene–drug combination
can, for instance, occur multiple times if the gene
is predicted to be targeted by more than one
miRNA. Also, multiple miRNAs are often deregu-
lated in the same disease tissue, and drug resistance
may therefore be the result of the combined actions
of several miRNAs working on different genes. Such
cases may be identified by using the ‘overlapping
associations’ option in Pharmaco-miR. For instance,
cancer cell line resistance to cisplatin has been asso-
ciated with down-regulation of four different genes
by seven different miRNAs [48–51]. Finally,
miRNA deregulation may only initiate a signaling
cascade which involves secondary effects that lead
to deregulation of several genes. This is exemplified
in a study by Giovannetti et al. [52], where in
gemcitabine-resistant pancreatic cancer cells,
miR-21 induction leads to an increase in
metalloproteinase-2 and 9 (MMP-2 and MMP-9)
and vascular endothelial growth factor (VEGF) ex-
pression levels as part of cell invasiveness. MMP-2,
MMP-9 and VEGF are therefore indirect, down-
stream targets of miR-21 that play a role in gemci-
tabine resistance. Such cases where genes are
deregulated due to secondary effects are not included
in Pharmaco-miR, since the database only includes
Table 3: PharmGKB VIP genes with experimentally validated miRNA targets and selected associated drugs, as
identified by Pharmaco-miR
Gene miRNAs Drugs (selected)
AHR miR-124, miR-375 GS-9350, omeprazole
BRCA1 miR-146a Mifepristone, tamoxifen
NR1I2 let-7a GS-9350, amlodipine, amoxicillin, ampicillin, antineoplastic agents, artemisinin and derivatives, aspirin, bexaro-
tene, budesonide, carbamazepine, cefadroxil, cefuroxime, celecoxib, chlorpromazine, cyclophosphamide,
cyclosporine, dexamethasone, diclofenac, diethylstilbestroldocetaxel, doxorubicin, econazole, erythromycin,
estradiol, estriol, etoposide, flurbiprofen, fluvastatin, glibenclamide, griseofulvin, hydrocortisone, ifosfamide,
isradipine, lansoprazole, lovastatin, meloxicam, methadone, miconazole, mifepristone, montelukast, nafcillin,
nevirapine, nifedipine, ondansetron, oxiconazole, paclitaxel, penicillin, phenobarbital, phenytoin, pravastatin,
progesterone, protease inhibitors, rabeprazole, reserpine, rifampin, ritonavir, saquinavir, simvastatin, sulfa-
methazine, sulfinpyrazone, tamoxifen, tetracycline, topotecan, troglitazone, valproic acid, vinblastine, vincris-
tine, vitamin D and analogs, xenobiotics
PTGS2 let-7b, miR-16 Anti-inflammatory agents, BSI-201, coxibs, olaparib, aspirin, capecitabine, celecoxib, cetuximab, clomipramine,
dexamethasone, diclofenac, gefitinib, glucocorticoids, HMG CoA reductase inhibitors, ibuprofen, interferon
alfacon-1, nimesulide, omega-3 polyunsaturated fatty acids, oxaliplatin, prostaglandins, rofecoxib, tacrolimus,
valdecoxib
TYMS let-7b Pyrimidine analogs, antimetabolites, antineoplastic agents, asparaginase, bevacizumab, capecitabine, carbopla-
tin, cisplatin, cyanocobalamin, cytarabine, daunorubicin, dexamethasone, etoposide, fluorouracil, folic acid,
gemcitabine, ibuprofen, irinotecan, L-glutamine, leucovorin, mercaptopurine, methotrexate, oxaliplatin, peme-
trexed, prednisone, pyridoxine, raltitrexed, vincristine
VDR let-7a, miR-125b Alendronate, asparaginase, calcipotriol, calcitriol, calcium, clodronate, cyclophosphamide, cyclosporine, cytar-
abine, daunorubicin, dexamethasone, estrogens, etidronic acid, etoposide, leucovorin, mercaptopurine,
methotrexate, prednisone, raloxifene, torcetrapib, tretinoin, vincristine, vitamin D and analogs
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direct targets, although Pharmaco-miR could be
used to determine candidates for direct targets in
gemcitabine resistance.
miRNAs AS DRUGS
Efforts are ongoing to develop miRNA-based drugs,
either in the form of miRNA mimics, amplifying the
impact of a miRNA, or miRNA inhibitors, essentially
quenching the effect of a miRNA. miRNA drugs
have the advantage that one miRNA may target
and modify the expression of several genes with dif-
ferent roles in the same pathway. The most advanced
miRNA drug to date is a miRNA inhibitor which
targets miR-122 in liver to treat hepatitis C virus
(HCV) [53]. One challenge as such drugs approach
clinical use is testing for interactions between the
novel miRNA drugs and traditional drugs already in
the market. The link from miRNAs to drugs allows
Pharmaco-miR to predict putative interactions be-
tween novel miRNA drugs and more traditional
drugs, which can then be tested experimentally.
miR-122 is for instance predicted to target estrogen
receptor 1 (ESR1), whose gene product is essential for
the important drug families of estrogens (e.g. estra-
diol) and anti-estrogens (e.g. tamoxifen). If this pre-
dicted target is functional, treating patients for HCV
with miR-122 may cause adverse drug effects if the
patient is also undergoing treatment with estrogens or
anti-estrogens.
CONCLUSION
In recent years, an increasing number of papers de-
scribe a link between miRNAs and drug function
through deregulation of pharmacogenomics relevant
genes. These studies are mainly performed in cancer
cell lines and mainly describe chemoresistance. Drug
toxicity studies and studies on drug metabolizers are
remarkable scarce. Also, many studies report miRNA
deregulation in drug-resistant cells but fail to identify
the miRNA target effector genes. The lack of such
studies highlights how elusive it can be to link
miRNA expression with the relationship between
genes and drug efficacy/toxicity. Pharmaco-miR is
a web server designed to assist in identifying such
interactions among miRNAs, target genes and asso-
ciated drugs by integrating the leading sources on
miRNA targeting and pharmacogenomics. The
output typically consists of miRNA pharmacoge-
nomic sets comprising a miRNA, a target gene and
a drug annotated in the literature as being associated
with the target gene. Accompanying Pharmaco-miR
is the VerSe database, consisting of miRNA pharma-
cogenomic sets which have been experimentally
verified. Pharmaco-miR is thus a useful tool when
predicting the effect of miRNAs on drug efficacy
and toxicity or when developing hypothesis within
miRNA pharmacogenomics. Identification of
miRNA pharmacogenomic sets makes it possible to
outline potential mechanisms for miRNA–drug
interactions when planning experiments and assists
in the interpretation of results. As the field of
miRNA pharmacogenomics matures, Pharmaco-
miR can be extended to collect relevant information
within the field and allow searches specifically for
miRNA pharmacogenomic sets, where the full set
has been investigated in a pharmacogenomic con-
text. We therefore believe that Pharmaco-miR will
contribute significantly to the progress of miRNA
pharmacogenomics both in short and long terms.
SUPPLEMENTARYDATA
Supplementary data are available online at http://
bib.oxfordjournals.org/.
Key Points
 MicroRNAs (miRNAs) play a role in pharmacogenomics by
regulating genes that are important for drug function.
 Theweb server Pharmaco-miR combinesmiRNA targeting data
with gene^drug interactions and thereby helps identify sets
of miRNAs, their target genes and drugs depending on these
genes for their action. Thus, Pharmaco-miR predicts inter-
actions betweenmiRNA regulation and drug function.
 Pharmaco-miR can be an important tool when planning and in-
terpreting miRNA pharmacogenomic experiments and building
hypothesis onmechanisms ofmiRNA^drug interdependence.
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